Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Allergy & Immunology
•
Pulmonology
•
Diffuse Parenchymal Lung Disease
•
Primary Immunodeficiency
How often are you performing CT screening in CVID patients to screen for ILD?
Answer from: at Academic Institution
CT once every 1-2 years, depending on symptoms and PFTs. PFTs, including DLCO, are annually performed.
Sign In
or
Register
to read more
30257
Related Questions
Are there certain clinical features that help you choose between benralizumab and mepolizumab for EGPA in clinical practice?
Are there benefits to adding IL5/IL5 receptor blockade in patients with vasculitic manifestations of EGPA?
Do you utilize cytokine panels to guide treatment of patients with EGPA?
Is it still significant to denote the etiology of ILD in a patient with PPF?
Is there any value to IgG subclasses in assessing immune deficiency in a patient with normal IgG levels?
Would you consider anti-IL-5 therapy (mepolizumab or benralizumab) to either prevent or treat the more severe manifestations of eosinophilic granulomatosis with polyangiitis, such as "infiltrative" (e.g., cardiomyopathy, pulmonary infiltrates, or gastroenteritis) or "vasculitic" (e.g., neuropathy, palpable purpura, or glomerulonephritis)?
Do you always get a baseline chest xray in patients who will be starting methotrexate?
What is the role of inebilizumab in the maintenance treatment of IgG4-related disease?
Should the RSV vaccine be administered to pregnant mothers even if it is not seasonally circulating but they are 32-36 weeks pregnant?
How do you manage pleuroparenchymal fibroelastosis in a patient with seronegative RA that is progressing on Rituxan and DMARD therapy?